1 中华医学会妇产科学分会绝经学组.激素补充治疗临床应用指南(2003年).中华妇产科杂志,2004,39:73-74.
2 中华医学会妇产科学分会绝经学组.绝经过渡期和绝经后激素治疗临床应用指南修订草案(2006版).中华妇产科杂志,2008,43:396-398.
3 中华医学会妇产科学分会绝经学组.绝经过渡期和绝经后期激素补充治疗临床应用指南(2009版).中华妇产科杂志,2010,45:635-638.
4 中华医学会妇产科学分会绝经学组.绝经期管理与激素补充治疗临床应用指南(2012版).中华妇产科杂志,2013,48:795-799.
5 de Villiers TJ,Pines A,Panay N,et al.Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health.Climacteric,2013,16:316-337.
6 郁琦.绝经学.北京:人民卫生出版社,2013:203-207.
7 Hulley S,Grady D,Bush T,et al.Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.Heart and Estrogen/progestin Replacement Study (HERS) Research Group.JAMA,1998,280:605-613.
8 Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial.JAMA,2002,288:321-333.
9 Simon JA.What's new in hormone replacement therapy:focus on transdermal estradiol and micronized progesterone.Climacteric,2012,15 Suppl 1:3-10.
10 Schierbeck LL,Rejnmark L,Tofteng CL,et al.Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women:randomised trial.BMJ,2012,345:e6409.
11 Sturdee DW,Pines A,Archer DF,et al.Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health.Climacteric,2011,14:302-320.
12 Estrogen and progestogen use in postmenopausal women:2010 position statement of The North American Menopause Society.Menopause,2010,17:242-255.
13 Tremollieres F,Brincat M,Erel CT,et al.EMAS position statement:Managing menopausal women with a personal or family history of VTE.Maturitas,2011,69:195-198.14 Wassertheil-Smoller S,Hendrix SL,Limacher M,et al.Effect of estrogen plus progestin on stroke in postmenopausal women:the Women's Health Initiative:a randomized trial.JAMA,2003,289:2673-2684.
15 Hendrix SL,Wassertheil-Smoller S,Johnson KC,et al.Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.Circulation,2006,113:2425-2434.
16 Lacey JV Jr,Sherman ME,Rush BB,et al.Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.J Clin Oncol,2010,28:788-792.
17 Varma R,Soneja H,Bhatia K,et al.The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.Eur J Obstet Gynecol Reprod Biol,2008,139:169-175.
18 Meier CR,Sturkenboom MC,Cohen AS,et al.postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus.J Rheumatol,1998,25:1515-1519.
19 Sanchez-Guerrero J,Gonzalez-Perez M,Durand-Carbajal M,et al.Menopause hormonal therapy in women with systemic lupus erythematosus.Arthritis Rheum,2007,56:3070-3079.
20 Vieira CS,Pereira FV,de Sa MF,et al.Tibolone in postmenopausal women with systemic lupus erythematosus:a pilot study.Maturitas,2009,62:311-316.
21 Hochman J,Urowitz MB,Ibanez D,et al.Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease.Lupus,2009,18:313-317.
22 Fernandez M,Calvo-Alen J,Bertoli AM,et al.Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II):relationship between vascular events and the use of hormone replacement therapy in postmenopausal women.J Clin Rheumatol,2007,13:261-265.
23 Beral V.Breast cancer and hormone-replacement therapy in the Million Women Study.Lancet,2003,362:419-427.
24 Cuzick J,Warwick J,Pinney E,et al.Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction:a nested case-control study.J Natl Cancer Inst,2011,103:744-752.
25 Harvey JA,Pinkerton JV,Baracat EC,et al.Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens.Menopause,2013,20:138-145.
26 Stevenson JC.Type and route of estrogen administration.Climacteric,2009,12 Suppl 1:86-90.
27 Kopper NW,Gudeman J,Thompson DJ.Transdermal hormone therapy in postmenopausal women:a review of metabolic effects and drug delivery technologies.Drug Des Devel Ther,2009,2:193-202.
28 Walsh BW,Spiegelman D,Morrissey M,et al.Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol.J Clin Endocrinol Metab,1999,84:985-989.

     (